---
title: "bioAffinity Tech | 8-K: FY2026 Q1 Revenue: USD 1.352 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285724946.md"
datetime: "2026-05-08T12:32:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285724946.md)
  - [en](https://longbridge.com/en/news/285724946.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285724946.md)
---

# bioAffinity Tech | 8-K: FY2026 Q1 Revenue: USD 1.352 M

Revenue: As of FY2026 Q1, the actual value is USD 1.352 M.

EPS: As of FY2026 Q1, the actual value is USD -0.81.

EBIT: As of FY2026 Q1, the actual value is USD -3.612 M.

#### Segment Revenue

-   CyPath® Lung testing revenue increased approximately 114% to $361,000 in the first quarter of 2026, compared to $169,000 in the first quarter of 2025.
-   Total consolidated revenue decreased approximately 27% to $1.4 million in the first quarter of 2026, compared to $1.9 million for the first quarter of 2025, primarily due to the discontinuation of certain unprofitable pathology services in March 2025.
-   Net Revenue for the three months ended March 31, 2026, was $1,351,527, down from $1,853,597 for the same period in 2025.

#### Operational Metrics

-   CyPath® Lung unit sales rose 146% year-over-year in the first quarter of 2026.
-   The number of physician offices and clinics ordering CyPath® Lung increased 69% from the first quarter of 2025 to the same period in 2026.
-   Total operating expenses for the first quarter of 2026 were $4,968,503, compared with $4,480,736 in the first quarter of 2025.
-   Direct costs and expenses were $928,636 for the first quarter of 2026, a decrease of 32% from $1,367,860 in the prior-year period.
-   Research and development expenses decreased 5% year-over-year to $349,707 in the first quarter of 2026, down from $367,386 in 2025.
-   Clinical development expenses rose to $334,040 in the first quarter of 2026, compared to $138,353 in 2025.
-   Selling, general and administrative expenses were $3,241,602 for the first quarter of 2026, up from $2,452,549 in the same period last year.
-   Depreciation and amortization was $114,518 for the first quarter of 2026, compared to $154,588 in 2025.
-   Loss from operations was -$3,616,976 for the first quarter of 2026, compared to -$2,627,139 for the first quarter of 2025.
-   Net loss for the quarter ended March 31, 2026, was -$3,630,610, compared with a net loss of -$2,660,417 for the first quarter of 2025.

#### Cash and Cash Equivalents

-   Cash and cash equivalents as of March 31, 2026, were $3.1 million, compared with $6.4 million as of December 31, 2025.

#### Outlook / Guidance

-   bioAffinity Technologies, Inc. expects growth to accelerate throughout 2026 due to planned commercial initiatives aimed at increasing awareness and adoption of CyPath® Lung. The company will focus on scaling commercial execution, expanding into new geographic markets, and driving increased utilization of CyPath® Lung through physician engagement. They also plan to leverage their flow cytometry and AI platform to advance their pipeline of diagnostics for serious lung diseases throughout the remainder of 2026.

### Related Stocks

- [BIAF.US](https://longbridge.com/en/quote/BIAF.US.md)

## Related News & Research

- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [Advance Auto Parts Reports First Quarter 2026 Results; Reaffirms Full Year 2026 Guidance | AAP Stock News](https://longbridge.com/en/news/287202242.md)
- [PRO REIT declares May 2026 cash distribution of $0.0375 per unit](https://longbridge.com/en/news/287207393.md)
- [LOWE'S REPORTS FIRST QUARTER 2026 SALES AND EARNINGS RESULTS | LOW Stock News](https://longbridge.com/en/news/287043063.md)